C646, a Novel p300/CREB-Binding Protein-Specific Inhibitor of Histone Acetyltransferase, Attenuates Influenza A Virus Infection

• Published in: Antimicrobial agents and chemotherapy Vol. 60; no. 3; pp. 1902 - 1906
• Main Authors: Zhao, Dongming, Fukuyama, Satoshi, Sakai-Tagawa, Yuko, Takashita, Emi, Shoemaker, Jason E., Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.03.2016
• Subjects: Animals; Antiviral Agents; Antiviral Agents - pharmacology; Benzoates; Benzoates - pharmacology; Cell Line; CREB-Binding Protein; CREB-Binding Protein - antagonists & inhibitors; CREB-Binding Protein - metabolism; Dogs; E1A-Associated p300 Protein; E1A-Associated p300 Protein - antagonists & inhibitors; E1A-Associated p300 Protein - metabolism; HEK293 Cells; Histone Acetyltransferases; Histone Acetyltransferases - antagonists & inhibitors; Humans; Influenza A virus; Influenza A virus - drug effects; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Orthomyxoviridae Infections - drug therapy; Pyrazoles; Pyrazoles - pharmacology
• ISSN: 0066-4804; 1098-6596; 1098-6596
• DOI: 10.1128/AAC.02055-15

New strategies to develop novel broad-spectrum antiviral drugs against influenza virus infections are needed due to the emergence of antigenic variants and drug-resistant viruses. Here, we evaluated C646, a novel p300/CREB-binding protein-specific inhibitor of histone acetyltransferase (HAT), as an anti-influenza virus agent in vitro and in vivo and explored how C646 affects the viral life cycle and host response. Our studies highlight the value of targeting HAT activity for anti-influenza drug development.